The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study.

Song, M; Kim, J H; Lee, K-S; Lee, J Z; Oh, S-J; Seo, J T; Choi, J B; Kim, S W; Rhee, S J; Choo, M-S

Song, M; Kim, J H; Lee, K-S; Lee, J Z; Oh, S-J; Seo, J T; Choi, J B; Kim, S W; Rhee, S J; Choo, M-S.

Affiliation

Song M; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Int J Clin Pract ; 69(2): 242-50, 2015 Feb.

Article in En | MEDLINE | ID: mdl-25363415

Subject(s)

Muscarinic Antagonists/therapeutic use; Receptor, Muscarinic M3/drug effects; Urinary Bladder, Overactive/drug therapy; Urinary Incontinence/drug therapy; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists/adverse effects; Placebos

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Incontinence / Muscarinic Antagonists / Receptor, Muscarinic M3 / Urinary Bladder, Overactive Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Pract Journal subject: MEDICINA Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google